生命科学资讯

Biotech’s groove is back for 2026 as XBI surges on M&A and lower rates

Insilico caps the year with a soaring Hong Kong IPO

Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blocker

Federal judge blocks 340B drug pricing pilot ahead of Jan. 1 effective date

ASK Pharm makes China rights deal; Unicycive resubmits kidney drug after CRL

Nido Bio to wind down after underwhelming Phase 2 data

As gene editing tools multiply, the hunt for the final technology continues

Ultragenyx, Mereo crash on late-stage bone disease failure

Genmab terminates Phase 3 lung cancer asset that BioNTech ditched

CMS unveils Medicare coverage model for weight loss drugs

Biohaven’s ion channel drug fails again, this time in major depressive disorder

J&J axes eczema drug from $1.25B acquisition

Agios finally wins approval for Aqvesme in thalassemia

Sanofi to buy hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug

Drugmakers with White House pricing deals may skirt new Medicare demos

Gilead's herpes deal; FDA approvals for Boehringer, Roche

Labcorp backs Cellens in developing physics test aimed at bladder cancer

Neurocrine’s Ingrezza flunks pivotal study in dyskinetic cerebral palsy

Updated: Pfizer discloses patient death in Hympavzi hemophilia trial

Novo Nordisk eyes a strong launch with FDA approval of obesity pill